Introduction {#sec1}
============

Mayer--Rokitansky--Küster--Hauser (MRKH) syndrome is characterized by congenital aplasia of the uterus and the upper part of the vagina. It affects around 1 in 5000 females ([@ref8]). The diagnosis is usually made in adolescence after the presentation of primary amenorrhea. Further examination reveals vaginal agenesis with absence of the uterus, normal secondary sex characteristics, and normal female 46,XX karyotype ([@ref3]). It may also be associated with renal and/or skeletal malformations, classified as atypical MRKH syndrome ([@ref22]; [@ref27]).

The etiology of the MRKH syndrome is unclear ([@ref25]). Embryological evidence supports the hypothesis that this syndrome occurs as a result of failure of Müllerian duct development. In the normal male embryo, the Sertoli cells of the testes produce anti-Müllerian hormone (AMH), resulting in regression of the Müllerian duct. This inhibitory action of AMH on the Müllerian duct starts during the fifth week of pregnancy and is progressive during the critical time window of uterine development ([@ref30]). Genetic activation of AMH or its receptor has been implicated as a cause of MRKH syndrome but without any supporting results ([@ref23]; [@ref28]).

In cattle, a similar phenotypical syndrome to MRKH exists: a so-called freemartin. In this infertile female calf, the absence of Müllerian structures occurs due to intrauterine AMH exposure, originating from a male co-twin ([@ref34]). Vascular connections in the placenta transport AMH from the male to the female calf ([@ref17]). As a result of this intrauterine blood exchange via the placenta, the freemartins are 'chimeras'; in addition to the normal XX cells, they have an extra XY cell line, originating from their co-twin. The term chimerism means that two genetically different cell lines are present in one individual, originating from more than one zygote.

In humans, intrauterine cell trafficking between twins can also result in chimerism ([@ref26]; [@ref33]). It is unknown whether this has clinical consequences. [@ref2]) reported a possible case of 'human freemartinism' in a female twin with aplasia of the uterus. In this female, blood exchange via the placenta with her brother had resulted in male chimerism (the presence of XY cells) ([@ref2]). In addition, a vanishing twin can leave its traces in the form of microchimerism, in which a second cell population is present at variable concentrations in the surviving fetus ([@ref1]).

It should also be mentioned that fetal--maternal exchange in a normal pregnancy is a well-known source for chimeric cells ([@ref18]). Fetal microchimerism refers to the phenomenon of fetal cells entering the maternal circulation during pregnancy. As the exchange between fetus and mother is bidirectional, the presence of maternal cells in the circulation of their children is called maternal chimerism. Chimerism can also occur following transplantation or blood transfusion ([@ref16]).

There have been no studies to date to examine the presence of male chimerism in women with the MRKH syndrome. The main purpose of the research reported here was to study whether the etiology associated with freemartinism could be the cause of the MRKH syndrome in humans. We hypothesized that a male---possibly vanished---co-twin was present during the early embryological development of women with MRKH syndrome, resulting in exchange of AMH via placental vascular connections. Therefore, we investigated the presence of male microchimerism (as a result of cell trafficking from male twin to female twin) in MRKH patients and compared these results with control women.

Materials and Methods {#sec2}
=====================

Study subjects {#sec3}
--------------

This observational case--control study compared the presence of male microchimerism in women with the MRKH syndrome and control women. Through recruitment via the Dutch patients' association of women with MRKH ('Stichting MRK-vrouwen'), we enrolled 96 women diagnosed with the MRKH syndrome (in total, the 300 members were informed by email or regular mail and the participation rate was 32%). All participants were 18 years or older and provided written informed consent prior to enrollment. Between January 2017 and July 2017, blood samples were obtained by venipuncture, by one researcher (H.E.P.). The blood samples were collected in EDTA vacutainer® tubes. All participants completed a questionnaire, comprising questions about demographic information, medical history, MRKH diagnosis, and family history.

The control group comprised women who volunteered to participate in an earlier study at our hospital. This study evaluated reproductive functioning in female childhood cancer survivors (DCOG LATER-VEVO study, NL15106.029.06) ([@ref24]; [@ref32]). For this study, women who did not have a history of cancer in the past were included as control subjects. Phenotypic data were collected between 2008 and 2014 by questionnaires, and biological material was collected via blood sampling. Out of the 390 women who provided biological material for the study, we selected 100 women who reported to have never been pregnant for the control group.

MRKH diagnosis {#sec4}
--------------

The MRKH diagnosis of the participants was confirmed by contacting the general practitioner or gynecologist, to retrieve the detailed information about the diagnosis based on physical examination, imaging or laparoscopy results. The patients were identified as having typical MRKH syndrome (also referred to as type 1) in case of no known other malformations and as atypical (type 2) MRKH syndrome when renal and/or skeletal malformations were present ([@ref22]).

Preparation of samples {#sec5}
----------------------

Genomic DNA was extracted from peripheral venous blood according to standard procedures. The extracted DNA was stored at −80°C until further processing. The DNA concentration ranged from 2.48 to 261 ng/μL (mean 77.47 ng/μL). The A260/A280 ratio ranged from 1.33 to 2.46 (mean 1.85).

Analysis of male microchimerism {#sec6}
-------------------------------

Real-time quantitative PCR (qPCR) was performed using a QuantStudio™ 7 Flex system (Applied Biosystems, Waltham, MA, USA). The DNA sequence utilized for detection of male genome targets a Y-chromosome specific region, *DYS14*. Amplification primers and probe sequences for *DYS14* have been described previously ([@ref15]). Also, the rationale for using this region as a Y-chromosome target is detailed ([@ref15]). As a measure of the total input quantity of genomic mass per reaction, qPCR of the *β-globin* gene was measured in parallel. Primers and probes for *β-globin* are also previously described ([@ref19]). All genome equivalent (GEq) conversions utilized a conversion factor of 6.6 pg DNA per cell ([@ref29]). Male GEq was reported per 1 million cells and calculated using the following equation:$$\documentclass[12pt]{minimal}
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}{}$$ C=\frac{Q_{DYS14}}{6.6 pg}\times \frac{6.6 pg\times {10}^6}{Q_{\beta -\mathrm{globin}}}, $$\end{document}$$where C = concentration of male GEq per 1 million cells, Q~DYS14~ = mean mass of *DYS14* (ng) determined by qPCR, and Q~β-Globin~ = mean mass of *β-globin* (ng) determined by qPCR.

Amplification measurement was accomplished using a dual-labeled minor groove binder probe with a 5′-bound fluorescent dye reporter \[6-carboxyfluorescein (FAM)\] and a 3′-bound non-fluorescent quencher. While both are bound to the probe, the fluorescent signature of the reporter is quenched. Taq DNA polymerase 5′-3′ exonuclease activity during the extension phase of PCR causes cleavage of the probe, releasing the FAM reporter ([@ref7]; [@ref9]). Once separated from the quencher, the reporter will emit its fluorescence ([@ref7]; [@ref15]). This fluorescent emission is detected by the Quantstudio™ 7 Flex system and analyzed by Quantstudio™ Real-Time PCR software (v 1.1) (Applied Biosystems, Waltham, MA, USA).

Calibration standards for the *DYS14* assay were produced by diluting known male DNA in female DNA to a total concentration of 66 ng/μL, with subsequent 10-fold dilutions ranging from 66 ng to 0.0066 ng male genome (mean *r*^2^ = 0.994, *n* = 11). Calibration standards for the β-globin assay were produced by 10-fold serial dilution of DNA, ranging from 500 ng---0.5 ng (mean *r*^2^ = 0.997, *n* = 11). All standards were measured in triplicate on each reaction plate simultaneously with subject reactions. Also included on each reaction plate were positive and negative control subjects for male genome diluted in female DNA and a no template control (NTC) for each assay. The negative controls and NTC tested consistently negative during all experiments.

Performance of the assay was measured for reproducibility and linearity by using female samples spiked with male DNA. A series of 10-fold dilutions of male DNA in female DNA demonstrated target specificity of the *DYS14* assay. The measured male GEq of our validation controls demonstrated excellent linear regression with a correlation coefficient of 0.998. Reproducibility was measured using three samples with mean male GEqs per million of 1594.64 ± 137.41 \[coefficient of variation (CV) = 8.62\], 10.50 ± 2.31 (CV = 22.02), and 6.72 ± 1.82 (CV = 27.14).

The qPCR reactions were set up in a 10 uL reaction on 384-well reaction plates. The target genome input of blood-extracted DNA was 66 ng per reaction, thus achieving 10 000 genomes per reaction. Each reaction also included 5.0 μL TaqMan® Fast Advanced Master Mix (Applied Biosystems, Waltham, MA, USA), 0.5 μL 20× custom assay (Applied Biosystems, Waltham, MA, USA) including a dual-labeled probe as well as forward and reverse primers. Each sample simultaneously tested 12 aliquots for *DYS14* and in duplicate for *β-globin* on the same reaction plate. The amplification thermal cycling initiated with 50°C for 2 min then denaturation at 95°C for 2 min then 46 cycles of 95°C for 15 s and 56°C for 1 min.

All qPCR reactions and analyses were performed by a scientist who was blinded to MRKH status. Results were reported as male GEq per 1 million cells, calculated by using the mean measure of *DYS14* and *β-globin* for each subject. Male microchimerism was defined as a quantifiable measure of *DYS14* in any of 12 aliquots tested per sample.

Precautions against contamination {#sec7}
---------------------------------

We utilized strict precautions while handling these samples to prevent contamination. Standard precautions for a PCR reaction set up were followed ([@ref14]). Separate pre-amplification and post-amplification areas were strictly adhered to. All handling of samples was done inside a class II biosafety cabinet, which pulls contaminated air from the work surface and exterior environment through a high efficiency particulate air (HEPA) filter to sterilize before returning to the work surface. All pipetting was carried out using aerosol-resistant filtered pipette tips. Each reaction plate included multiple NTC wells for each assay. After each use and preparation of each plate, the biosafety cabinet was thoroughly cleaned using a system of 10% bleach, cleaned with deionized water, followed by DNAZap™ (Invitrogen, Waltham, MA, USA) as per manufacturer's directions, two cycles of deionized water cleaning and 1 h of an ultraviolet lamp.

###### 

Reported malformations in 41 women with atypical Mayer--Rokitansky--Küster--Hauser syndrome.

  Malformations                          
  -------------------------------------- -------
  Renal (28/41)^\*^                      (*n*)
  Unilateral renal agenesis              15
  Pelvic kidney                          3
  Hypoplastic kidney                     3
  Horse shoe kidney                      2
  Abnormal position                      2
  Malrotation                            1
  Cirrhotic kidney                       1
  Duplex kidney                          1
  Skeletal (18/41)^\*^                   
  Scoliosis                              13
  Cervical ribs                          1
  Arm agenesis                           1
  Scoliosis and fusion of vertebrae      1
  KFS, SD, and scoliosis                 1
  Spina bifida, KFS, SD, and scoliosis   1
  Other (4/41)^\*^                       
  Hearing loss                           2
  Scaphoid hypoplasia and hearing loss   1
  Clubfoot                               1

^\*^Combined malformations in nine women. KFS, Klippel--Feil syndrome (cervical vertebral fusion); SD, Sprengel's deformity (high scapula).

Statistical analysis {#sec8}
--------------------

For sample size calculation, we assumed 25% microchimerism in the control group \[according to results in previous studies ([@ref35])\], and we assumed that in at least 50% of the adult women with MRKH syndrome, male microchimerism would still be detectable in the blood. With a significance level (alpha) of 5% and a power of 95%, we calculated a sample size of 91 women in both groups. Anticipating a 5% margin of error, in total, 192 women needed to be included.

Not normally distributed variables were compared using the Mann--Whitney U test. For categorical variables, the chi-squared (χ^2^) or Fisher's exact test was used as appropriate. We used logistic regression to examine the association between microchimerism and MRKH syndrome by calculating the odds ratio (OR). Age (years) was included as a covariate as it may affect the presence of microchimerism. *P* \< 0.05 was considered statistically significant. The statistical analysis was performed using SPSS 22.0 (SPSS, Chicago, IL, USA).

Ethics {#sec9}
------

The study protocol has been approved by the Institutional Review Board of the VU Medical Center, Amsterdam, the Netherlands, on 5 January 2017 (METC VUmc 2016.374). The trial was registered in the Dutch National Trial Registry (trial registration number NTR5961).

Results {#sec10}
=======

For this study, 96 women were included in the MRKH group, and 100 control women were selected who reported to have never been pregnant. After collection of all available information, we excluded one woman in the patient group because, in retrospect, she did not have the MRKH syndrome. In the control group, one subject was excluded due to the limited amount of extracted DNA available for the microchimerism analysis. The final analysis included 194 women.

###### 

Male microchimerism in study subjects.

  Total group (*n* = 194)                                             MRKH (*n* = 95)                                               Control (*n* = 99)       *P*-value
  ------------------------------------------------------------------- ------------------------------------------------------------- ------------------------ ---------------
  Age (years)                                                         40.9 (15.5)                                                   30.2 (6.6)               ---
  BMI (kg/m^2^)                                                       24.3 (5.3)                                                    22.8 (3.5)               ---
  Presence of male microchimerism                                     5 (5.3%)                                                      17 (17.2%)               0.009^a^
                                                                      *OR^c^: 0.27 (CI 0.10--0.76)* *OR^d^: 0.17 (CI 0.05--0.63)*                            
  Concentration of male microchimerism (GEq^\*^)                                                                                                             
  Positive samples (n = 22)                                           2.3 (1.5)                                                     71.8 (127.0)             0.055^b^
  Total group                                                         0.1 (0.6)                                                     12.3 (58.1)              0.007^b^
  **Selection of study subjects with no older brother (*n* = 134)**   **MRKH (*n* = 63)**                                           **Control (*n* = 71)**   ***P*-value**
  Age (years)                                                         38.1 (12.9)                                                   30.5 (6.5)               ---
  Presence of male microchimerism                                     3 (4.8%)                                                      10 (14.1%)               0.069^a^
                                                                      *OR^c^: 0.31 (CI 0.08--1.16)* *OR^d^:0.18 (CI 0.03--0.90)*                             
  Concentration of male microchimerism (GEq^\*^)                                                                                                             
  Positive samples (*n* = 13)                                         1.3 (0.3)                                                     27.3 (67.1)              0.018^b^
  Total group                                                         0.1 (0.3)                                                     3.9 (25.9)               0.053^b^

Data are mean (SD) or *n* (%). MRKH, Mayer--Rokitansky--Küster--Hauser syndrome.

^\*^Male genome equivalents (GEq) per 1 000 000 female cells

^a^Chi-squared test

^b^Mann--Whitney U test

^c^Unadjusted odds ratio (95% confidence interval), logistic regression

^d^Odds ratio (95% confidence interval), adjusted for age

Patient characteristics {#sec11}
-----------------------

All women in the patient group reported having been diagnosed with the MRKH syndrome, with a mean time since diagnosis of 25.5 years (range 2--64 years). The mean age at the time of diagnosis was 16.5 years (range 6--26 years). In five women (5.3%), confirmation of the MRKH diagnosis by medical records could not be achieved. In total, 54 women (56.8%) were identified as having typical MRKH syndrome, and 41 women (43.2%) were identified as having atypical MRKH syndrome. For the women with atypical MRKH syndrome, 28 out of 41 (53.7%) had a renal malformation, 18 (24.4%) had a skeletal malformation, and 9 (22.0%) had combined malformations (Table [I](#TB1){ref-type="table"}). Of the participants in the patient group, three (3.2%) reported a positive family history for MRKH syndrome: two sisters were both participants in this study, and one woman reported an affected cousin (daughter of sister of father of participant). Two women with MRKH syndrome were part of dizygotic twin pairs, one with a twin brother and one with a twin sister, the latter twin sister being unaffected for the MRKH syndrome. All pregnancies resulting in the birth of a woman with MRKH syndrome were conceived naturally. The mean age of the mother at the time of birth of the women with MRKH syndrome was 28.7 years (range 18--42 years). All women in the control group reported having reached menarche and had never been pregnant. No women in the control group were part of a twin pair.

Male microchimerism {#sec12}
-------------------

In total, 194 women were included in the analyses concerning male microchimerism (Table [II](#TB2){ref-type="table"}). In the total group, 22 out of 194 (11.3%) women tested positive for male microchimerism. The prevalence of male microchimerism was significantly higher in the control group than in the MRKH group (17.2% versus 5.3%, *P* = 0.009) (Fig. [1](#f1){ref-type="fig"}). After correcting for age, women in the control group were 5.8 times more likely to have male microchimerism (OR 5.84 (95% CI 1.59--21.47), *P* = 0.008). The mean concentration of male microchimerism in the positive samples was 56.0 male GEq per 1 000 000 cells (Fig. [2](#f2){ref-type="fig"}). The mean concentration of male microchimerism was significantly higher in the control group than in the MRKH group (*P* = 0.007). The prevalence of male microchimerism was similar in women with typical MRKH syndrome and atypical MRKH syndrome (5.6% versus 4.9%, *P* \> 0.999).

![Number of subjects with male microchimerism in blood in control women and women with Mayer--Rokitansky--Küster--Hauser syndrome.\
MRKH, Mayer-Rokitansky-Küster-Hauser; statistical test used: chi-squared test.](dez044f1){#f1}

![Calculated male GEq per 1 million cells in blood, for control women and women with MRKH syndrome.](dez044f2){#f2}

To account for a possible older brother as a source for chimerism ([@ref4]), we made a subgroup analysis. From the total group, 134 women (69.1%) had no older brother (Table [II](#TB2){ref-type="table"}). Also in this subgroup, the prevalence and concentration of male microchimerism were higher in the controls than in the MRKH group.

###### 

Identifying additional sources for male microchimerism.

                           Male microchimerism positive (*n* = 22)   Male microchimerism negative (*n* = 172)   *P*-value
  ------------------------ ----------------------------------------- ------------------------------------------ ------------
  Age (years)              35.3 (11.6)^+^                            35.4 (13.1)                                ---
  Study group                                                                                                   
   MRKH                    5 (22.7%)                                 90 (52.3%)                                 0.009^a^
   Control                 17 (77.3%)                                82 (47.7%)                                 
  Older brother                                                                                                 
   yes                     9 (40.9%)                                 50 (29.1%)                                 0.263^a^
   no                      13 (59.1%)                                121 (70.3%)^\#^                            
  Blood transfusion\*                                                                                           
   yes                     0                                         5 (5.6%)                                   \>0.999^b^
   no                      5 (100%)                                  85 (94.4%)                                 
  Sexual intercourse\*\*                                                                                        
   yes                     16 (94.2%)                                75 (91.5%)                                 \>0.999^b^
   no                      1 (5.9%)                                  7 (8.5%)                                   

Data are mean (SD) or *n* (%).

^\*^Data missing for control women; this question was only asked in questionnaire for MRKH women.

^\*\*^Data missing for MRKH women; this question was only asked in questionnaire for control women.

^+^Mean (SD) age in women with MRKH syndrome who tested positive for microchimerism = 49.9 (10.9) years; age in control women = 31.0 (7.9) years.

^\#^One MRKH woman with a twin brother tested negative for male microchimerism.

^a^Chi-squared test

^b^Fisher's exact test

Table [III](#TB3){ref-type="table"} presents possible sources for male microchimerism. No significant difference was found for the prevalence of male microchimerism in the group with an older brother as opposed to the group without (*P* = 0.263). In the MRKH group, five women reported having received a blood transfusion; these women all tested negative for male microchimerism. The prevalence of male microchimerism wassimilar when comparing the group with and without blood transfusion (*P* \> 0.999). In the control group, eight women reported never having had sexual intercourse; of these women, one tested positive for male microchimerism. The prevalence of male microchimerism was similar when comparing the group with and without sexual intercourse (*P* \> 0.999).

Discussion {#sec13}
==========

MRKH is a condition that has been well characterized yet the etiology has remained elusive ([@ref5]). Research of the phenotype analogous condition in cattle, freemartinism, has yielded the hypothesis that uterine development is inhibited by exposure to AMH *in utero* ([@ref34]). In cattle, the male co-twin has been identified as the source of AMH, which is transferred via placental blood exchange. In humans, a similar exchange of cellular material has been documented between twins by detection of blood chimerism ([@ref26]; [@ref33]). We sought to explain fetal exposure to blood and AMH from a male (vanished) co-twin in women with MRKH by the measure of male blood microchimerism.

The use of a male genome target has been previously implemented in other studies of chimerism including fetal microchimerism ([@ref15]). However, to our knowledge, there are no studies to date that have explored the presence of male microchimerism in women with MRKH. Our approach utilized a qPCR technique that was able to demonstrate exceptional target specificity and sensitivity for male genome. In this study of 194 women, 5 of 95 women (5.3%) with MRKH demonstrated male microchimerism, while the control group demonstrated male microchimerism in 17 of 99 (17.2%). This difference shows a significantly lower frequency in detection of male microchimerism for women with MRKH (*P* = 0.009). Similarly, when subjects with older brothers are removed, the percentage of male microchimerism in controls and cases are 14.1% and 4.8%, respectively. Our results do not support increased male microchimerism in adult women with MRKH as a consequence of intrauterine blood exchange.

Although these results contradict our underlying hypothesis of inadvertent AMH exposure in early pregnancy as the pathophysiological mechanism, it is too early to definitively conclude that occurrence of AMH exchange during early embryologic development in MRKH was not involved. There are several limitations to our approach that must be considered. First, this method relies on the detection of male genome in these subjects and is therefore contingent on the occurrence of cell grafting as a consequence of this exchange. There are several factors that are essential to effective grafting of cellular material in a host in order to evade immune targeting and thrive ([@ref10]). It is possible for intrauterine cellular exchange to occur passively between twins and not result in a persistent chimerism. Similarly, our subject population includes all adult women and therefore is reliant on long-term prevalence of the male (XY) cell population to be detected at this stage of life. These XY cells may be eliminated or never graft in the host body, thereby shortening the timespan where detection is achievable. This technique exclusively examines the blood-derived genome, resulting in a limited scope of microchimerism detection and is not a global representation of chimerism throughout the individual. Owing to the proposed transfusion mechanism, it is most plausible that a male cell population may be localized in the blood; however, the cells may have grafted anywhere in the body during development ([@ref13]). It must also be considered that the exchange of AMH may occur without the transfusion of XY cells and therefore cannot be discovered by chimerism detection.

Our finding of male microchimerism in a larger percentage of women (17.2%) in the control group without a history of pregnancy is in line with findings from the literature. Prior studies demonstrated male microchimerism being present in 13.6% of adolescent girls ([@ref20]) and 13.3% of healthy null gravid women ([@ref35]). Potential sources for the male cells are considered to be transfusion ([@ref31]), older brothers (or discontinued male pregnancies from their mother) ([@ref4]), unrecognized male miscarriages ([@ref35]), vanishing twins ([@ref1]), or possibly sexual intercourse without pregnancy ([@ref20]). The significant difference in our study, in favor of the control group, suggests that a substantial proportion of the microchimerism could be explained by unrecognized pregnancies or the harboring of microchimeric cells after sexual intercourse. Moreover, the higher concentration in the control group could reflect a larger transfusion of microchimeric cells by these sources. In our study, there were no differences in occurrence of older brothers, previous blood transfusion, or history of sexual intercourse between women with or without microchimerism, both in participants and controls. We are unable to rule out the potential for microchimerism resulting from an unrecognized pregnancy or a vanishing twin.

The findings in women with MRKH illustrate that this population has a decreased prevalence of male microchimerism relative to others. This significant difference demonstrates that women with MRKH may serve as a suitable control group in chimerism research, in part due to the certainty that they have no history of pregnancy. Still, three women with MRKH and no older brother had detectable microchimerism, which may have been obtained through several mechanisms including a vanishing twin or miscarriage in their mother.

Considering the several potential sources of XY cells, our results from the control population demonstrate that there may be a larger prevalence of microchimerism in the general population, which requires further investigation. In general, there is increasing interest in the clinical consequences of microchimerism ([@ref6]; [@ref12]). It has been associated with various autoimmune disorders ([@ref21]), but possible beneficial consequences have also been described. Microchimeric cells could replace injured cells in diseased tissues ([@ref12]). Recently, it has been suggested that naturally acquired microchimerism has 'protective effects in promoting success of future pregnancies' ([@ref11]).

In summary, we hypothesized that women with MRKH syndrome had an unrecognized male co-twin that was lost early in gestation (a vanishing twin) and have investigated possible fetal exposure to male blood by measurement of male microchimerism. We are led to the conclusion that women with MRKH syndrome are not evident (micro)chimeras. However, we are not able to draw definitive conclusions regarding the occurrence of AMH exchange. Further research should involve the presence of MRKH syndrome in a large cohort of girls with a twin brother and in girls born after a pregnancy complicated by vanishing twin syndrome. Additional research on twin chimerism is needed to study the true prevalence of intrauterine blood exchange between dizygotic twins.
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